2 results match your criteria: "Clinical Center of the Champalimaud Center for the Unknown[Affiliation]"
Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness.
Pharmacoeconomics
May 2021
Hematology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Article Synopsis
- Multiple myeloma (MM) is a prevalent and costly hematological cancer in Portugal, with increasing incidence and significant health impacts.
- The study evaluates the disease burden using disability-adjusted life-years (DALYs) and estimates healthcare expenses incurred by the National Health Service (NHS), totaling around €61 million annually.
- Findings indicate that the majority of the burden from MM is due to premature mortality rather than disability, highlighting the need for informed health policies and resource allocation to improve patient care.
Multiple myeloma in elderly patients-a Portuguese multicentric real-life study.
Ann Hematol
July 2019
Hematology Department, Hemato-oncology Unit, Clinical Center of the Champalimaud Center for the Unknown, Av Brasilia, 1400-038, Lisbon, Portugal.
Article Synopsis
- * Data from 386 patients were analyzed, revealing that those on bortezomib-based protocols had better treatment responses and overall survival compared to thalidomide-based and chemotherapy protocols, especially in fitter patients.
- * While those treated with chemotherapy were generally older and had more health issues, the study noted lower severe side effects in patients on thalidomide or chemotherapy compared to bortezomib, underscoring the need for tailored treatment for older adults with multiple myeloma.